徐寒梅，女，中国药科大学教授，博士生导师，海洋药学教研室主任。海南省药物研究所顾问；中国生物化学与分子生物学会海洋生物化学与分子生物学分会理事会理事。自2002年于南京大学国家医药生物技术重点实验室进行博士后研究期间，开始抗肿瘤蛋白质及多肽的研究。2004年底到中国药科大学工作，继续从事抗肿瘤多肽的研究，带领团队主持设计合成了抗肿瘤多肽安替安吉肽（HM-3）,AP25，EDSM等具有自主知识产权的多肽，其中安替安吉肽已经获得临床批件，为1.1类化学新药。近五年在国内外发表学术文章50余篇，主编及参编论著各一部，主编教材一部；申请发明专利共23项(其中国际专利5项，其中第一发明人20项)。近5年以来，先后主持了：国家自然科学基金，国家“863”高科技发展计划，国家“重大新药创制”科技重大专项，江苏省校企合作前瞻性研究等项目。因与企业合作抗肿瘤多肽研究的表现获得内蒙古自治区“杰出创新引进人才”奖，“草原英才”；近五年先后获得江苏省“青蓝工程”优秀骨干教师，中青年学术带头人，南京市领军人才等奖励和称号；因为产学研合作的表现被内蒙古自治区政府聘为科技特派员;被教育部“蓝火工程”聘为泰州市科技特派员。

近五年以第一作者或通讯作者发表的与血管抑制剂相关的文章
1.JialiangHu,MingYan,ChunyanPu,JingjingWang,PhilippeE.Vandensteen,GhislainOpdenakker,HanmeiXu*.Chemicallysynthesizedmatrixmetalloproteinase-andangiogenesis-inhibitingpeptidesasanticanceragents.Anti-cancerReagentsME.2013(acceptedforpublication).
2.ZhengQiu,JialiangHu,HanmeiXu*,WenjingWang,ChunyanPu,XiangWang.Generationofanti-tumorpeptidesbyconnectionofmatrixmetalloproteinase-9peptideinhibitortoanendostatinfragment.Anti-CancerDrugs.2013,24:677-689.
3、LiYongbing,XuHanmei*,HuJialiang,ZhangFengguo,LiuZhendong,ZhangChi,YangYongjing,PuChunyan,QuantitativeAnalysisandPharmacokineticsStudyofIntegrinAntagonistAP25inRatPlasma,ProteinPeptLett.2013，20(5):584-90.
4.ChunyanPu，HanmeiXu*,JialiangHu,ZhengHeng,XiaofengHuang,ZhangChi;YongjingYang,YongbingLi,RGDpositionhaseffectonanti-angiogenicactivityofRGDmodifiedendostationderivedsyntheticpolypeptides.Anti-cancerdrugs.2012,12:788-802
5.LiPan¹,JialiangHu¹,WenjingWang¹,XiaojuanZhang¹,JinWei¹,ZhendongLiu¹,YihuaZhang^2*andHanmeiXu^1*.MolecularMechanismsof(R,R)ZX-5onNOSynthesisandItsAnti-AngiogenicEffect.InternationalJournalofMolecularSciences.2012,13,2717-2726.
6.LiuZhendong,LiWeiguang,XuHanmei^*,HuangXiaofeng,PanLi,RenYinling,YangYongjing,LiYongbing,PuChunyan,ZhangChi.Invivopharmacokinetics,immunogenicityandmechanismofPEGylatedanti-tumorpolypeptide.CurrentPharmaceuticalDesign.2012,18(12):1655-1662.
7.GuoqiuWu,XuepengDeng，PengpengWu,ZilongShen,HanmeiXu*,SubacutetoxicityofantimicrobialpeptideS-thanatininICRmice.Peptides2012,36(1):109-13.
8.HanmeiXu*,LiPan,YinlingRen,etal.AnRGD-ModifiedAngiogenesisInhibitorHM-3Dose:DualFunctionduringCancerTreatment.BioconjugateChem.,2011,22(7):1386–1393.
9.ZhendongLiu,YinlingRen,LiPanandHan-MeiXu*,InVivoAnti-TumorActivityofPolypeptideHM-3ModifiedbyDifferentPolyethyleneGlycols(PEG).Int.J.Mol.Sci.2011,12(4),2650-2663.
10.GuoqiuWu,XuepengDeng,HanmeiXu*,etal.ApplicationofimmobilizedthrombinforproductionofS-thanatinexpressedinEscherichiacoli.ApplMicrobiolBiotechnol.2011,92(1):85-93.
11.Han-MeiXu,JinWei,ZilongShen1*,etal.TheMechanismof(R,R)ZX-5PromotingChoroidalBloodFlowandIncreasingNORelease,Int.J.Mol.Sci.2010,11(9),3323-3333.
12.Ning-HuaTan,Yu-MeiZhang,Han-MeiXu*,etal.ANewAbietaneDiterpenefromGlyptostrobuspensilis,Fitoterapia,2010,81(8):1202-4.
13.KangZhou,BeiliZhu,Han-MeiXu*,etal.StudiesofpolyethyleneglycolmodificationofHM-3polypeptides，Conferencepaperof2010NanjingInternationalSymposiumonPharmacogenomicsandtheRegulationofDrugMetabolismEnzymesandGenes,JournalofNanjingUniversity,2010,Vol.46,127-132
14.BeiliZhu,Han-MeiXu*,Limingzhao,etal.Site-specificmodificationofantiangiogenesispeptideHM-3bypolyethyleneglycolmolecularweightof20kDa,JournalofBiochemistry,2010,148(3):341-347
15.RuntingYin,TaoXiandHan-MeiXu*,etal.EffectofRGD-4CPositionisMoreImportantThanDisulfideBondsonAntiangiogenicActivityofRGD-4CModifiedEndostatinDerivedSyntheticPolypeptide,bioconjugatechemistry,2010,6(1):1142-1147
16.ZhouK,ZhengXQ,XuHM*,etal.StudiesofPoly(ethyleneglycol)ModificationofHM-3Polypeptides,bioconjugatechemistry,2010,20(5):932-936.
17.Han-MeiXu^*,RuntingYin,XianghuaChen,etal.AnRGD-modifiedendostatin-derivedsyntheticpeptideshowsantitumoractivityinvivo，bioconjugatechemistry,2008,19(10):1980-1986.
18.SirajSami,Han-MeiXu^*,ZilongShen,etal.ValproicAcidInhibitstheGrowthofCervicalCancerbothInvitroandInvivo,JournalofBiochemistry,2008，144(3):357-362.